The first non-stimulant drug designed to treat attention-deficit/hyperactivity disorder won approval Tuesday from the Food and Drug Administration.
Indianapolis-based Eli Lilly and Co. expects Strattera to be available in pharmacies in January.
Lilly has tested Strattera on more than 4,000 patients, some for as long as 2 1/2 years. It has not been tested in children under 6.
Strattera is the first drug to be approved for ADHD that is not a stimulant under the federal Controlled Substances Act. The drug comes in a capsule and can be taken once or twice a day. Lilly said it provides full-day relief from the symptoms of ADHD.
MyWay APnews